Atai Beckley Inc. (ATAI)
$7.35+0.00%Close
BUYBULL · day 36
Key stats
- Market cap
- $2.7B
- Beta
- 1.55
- Div yield
- 91.84%
- P/E (TTM)
- -2.53
- 1W
- +0.14%
- 1M
- +1.66%
- vs SPY 1W
- +1.12%
- vs SPY 1M
- -0.21%
Industry peers
FMP comparable companies · ranked by market cap
- DNTHSELLDianthus Therapeutics, Inc.$4.6BCRISISQ 1$82.37-3.63%
- RLAYSELLRelay Therapeutics, Inc.$3.9BRECOVERYQ 2$17.88-1.73%
- AMLXSELLAmylyx Pharmaceuticals, Inc.$3.1BCRISISQ 7$28.14+0.67%
- ELVNSELLEnliven Therapeutics, Inc.$2.9BCRISISQ 11$40.98-0.53%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.5BCRISISQ 15$16.99-3.01%
- INBXSELLInhibrx Biosciences Inc.$1.4BCRISISQ 31$95.01-2.09%
- ORICSELLORIC Pharmaceuticals, Inc.$1.2BBEARQ 3$11.99+2.48%
- NKTRSELLNektar Therapeutics$1.2BCRISISQ 12$41.17-2.72%
- IMTXSELLImmatics N.V.$996MCRISISQ 5$7.43+2.49%
- SANASELLSana Biotechnology, Inc.$776MCRISISQ -7$2.79-3.32%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 19
- GARP
- 5
- TYPE
- Dividend Compounder
Composite of Value · Growth · GARP
ROIC-211.9%
REV YoY-
ROE-353.2%
EPS YoY-
ROA-252.3%
GROSS86
OP-3274
NET-14938
[VALUATION]
P/E TTM-2.53
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B15.03
P/FCF-
EV/EBITDA-3.77
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E2.43
ALTMAN Z-
CURR RATIO8.58
ND/EBITDA-
BETA1.55
POTENTIAL YIELD TRAP (YIELD 91.8% WITH PAYOUT/LEVERAGE/GROWTH STRESS)
Company news
FAQ
- What is LOPJLB’s current signal on ATAI?
- LOPJLB’s latest quantitative signal on Atai Beckley Inc. (ATAI) is BUY in a BULL regime. Signals are updated daily.
- What market regime is ATAI in?
- Atai Beckley Inc. (ATAI) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Atai Beckley Inc. (ATAI) do?
- Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation…